| 鹿丽 李冬娟 李明明 孙启政 孙婷婷 孙海玲.维生素B12 联合依帕司他对糖尿病周围神经病患者血清SOD及MDA水平的影响[J].,2017,17(6):1146-1148 |
| 维生素B12 联合依帕司他对糖尿病周围神经病患者血清SOD及MDA水平的影响 |
| Influence of Vitamin B12 Combined with Epalrestat on SerumSODand MDA Levels in Patients with Diabetic Peripheral Neuropathy* |
| |
| DOI： |
| 中文关键词: 维生素B12 依帕司他 糖尿病周围神经病 超氧化物歧化酶 丙二醛 |
| 英文关键词: Vitamin B12 Epalrestat Diabetic Peripheral neuropathy SOD MDA |
| 基金项目:山东省自然科学基金项目（20120016） |
|
| 摘要点击次数: 710 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨维生素B12 联合依帕司他对糖尿病周围神经病患者血清超氧化物歧化酶（SOD）及丙二醛（MDA）水平的影响。方
法：收集我院收治的98 例2 型糖尿病伴周围神经病变患者，随机分为实验组和对照组，每组49例。对照组患者给予依帕司他片
50 mg/次，3 次/d；实验组患者在对照组基础上给予维生素B12 25~100 滋g/ 次，1 次/d，治疗连续4 周。观察并比较两组患者周围
神经评分（TCSS 评分）、血清SOD、MDA 水平以及临床疗效。结果：与治疗前相比，两组患者的TCSS 评分、MDA水平均下降，血
清SOD 水平升高，差异具有统计学意义（P<0.05）；与对照组相比，实验组患者的TCSS 评分、丙二醛（MDA）水平较低，血清SOD
水平较高，差异具有统计学意义（P<0.05）；与对照组相比，实验组患者的治疗总有效率较高，差异具有统计学意义（P<0.05）；两组
患者均未有明显的不良反应，差异无统计学意义（P>0.05）。结论：维生素B12 联合依帕司他能够改善糖尿病周围神经病患者血清
MDA、SOD 水平，对临床有指导意义。 |
| 英文摘要: |
| Objective:To investigate the effect of vitamin B12 combined epalrestat on the serum superoxide dismutase (SOD),
malondialdehyde (MDA) level in patients with diabetic peripheral neuropathy.Methods:98 cases of Type 2 diabetes combined with
peripheral neuropathy in our hospital were randomly divided into experimental group and control group, with 49 cases in each group. The
patients in control group were treated with epalrestat tablet 50 mg/time, 3 times daily, and the patients in the experimental group were
given vitamin B12 25~100 g / time, once a day based on the control group, treatment for 4 weeks. The peripheral nerve scores (TCSS
score), serum SOD and MDA levels and clinical efficacy were observed and compared between the two groups.Results:Compared with
before treatment, the TCSS score, MDA level was decreased, and the level of SOD was increased after treatment in the two groups, and
the difference was statistically significant (P < 0.05). Compared with the control group, the TCSS score, serum MDA level was lower,
and the serum SOD level was higher in the experimental group, and the difference was statistically significant (P < 0.05). Compared with
the control group, the total effective rate was higher in the experimental group with statistical significance (P < 0.05); there were no
obvious adverse reactions in the two groups, and the difference was not statistically significant (P>0.05).Conclusion:Vitamin B12
combined epalrestat can reduce the serum MDA level and increase SOD level in treatment of diabetic peripheral neuropathy, and its
clinical curative effect is good. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
